A Study of Omega-3 Fatty Acids Has Negative Results

An omega-3 formulation of eicosapentaenoic acid and docosahexaenoic acid was not associated with a reduction in cardiovascular events in high-risk patients.

Studies on the use of omega-3 fatty acids to reduce residual cardiovascular risks have yielded mixed results. In the industry-funded STRENGTH trial, researchers have now assessed the effects of a carboxylic acid formulation (omega-3 CA) of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on clinical outcomes; the formulation was thought to yield greater bioavailability.

The 13,078 participants were at high cardiovascular risk (patients with atherosclerotic cardiovascular disease, those with diabetes plus at least 1 other risk factor, and high-risk primary-prevention patients) and were randomized to receive omega-3 CA (4 g/day) or corn oil (placebo). Participants also were stably treated with a statin; either had LDL levels <100 mg/…

Reviewing Author

Fatima Rodriguez, MD, MPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardNovoNordisk; HealthPals; Novartis; Amgen

EquityHealthPals; Carta

Grant/Research SupportNational Institutes of Health/National Heart, Lung, and Blood Institute; American Heart Association–Robert Wood Johnson Foundation

Editorial BoardsCardiology and Therapy